Literature DB >> 10923036

Spectrum of CFTR mutations in cystic fibrosis and in congenital absence of the vas deferens in France.

M Claustres1, C Guittard, D Bozon, F Chevalier, C Verlingue, C Ferec, E Girodon, C Cazeneuve, T Bienvenu, G Lalau, V Dumur, D Feldmann, E Bieth, M Blayau, C Clavel, I Creveaux, M C Malinge, N Monnier, P Malzac, H Mittre, J C Chomel, J P Bonnefont, A Iron, M Chery, M D Georges.   

Abstract

We have collated the results of cystic fibrosis (CF) mutation analysis conducted in 19 laboratories in France. We have analyzed 7, 420 CF alleles, demonstrating a total of 310 different mutations including 24 not reported previously, accounting for 93.56% of CF genes. The most common were F508del (67.18%; range 61-80), G542X (2.86%; range 1-6.7%), N1303K (2.10%; range 0.75-4.6%), and 1717-1G>A (1.31%; range 0-2.8%). Only 11 mutations had relative frequencies >0. 4%, 140 mutations were found on a small number of CF alleles (from 29 to two), and 154 were unique. These data show a clear geographical and/or ethnic variation in the distribution of the most common CF mutations. This spectrum of CF mutations, the largest ever reported in one country, has generated 481 different genotypes. We also investigated a cohort of 800 French men with congenital bilateral absence of the vas deferens (CBAVD) and identified a total of 137 different CFTR mutations. Screening for the most common CF defects in addition to assessment for IVS8-5T allowed us to detect two mutations in 47.63% and one in 24.63% of CBAVD patients. In a subset of 327 CBAVD men who were more extensively investigated through the scanning of coding/flanking sequences, 516 of 654 (78. 90%) alleles were identified, with 15.90% and 70.95% of patients carrying one or two mutations, respectively, and only 13.15% without any detectable CFTR abnormality. The distribution of genotypes, classified according to the expected effect of their mutations on CFTR protein, clearly differed between both populations. CF patients had two severe mutations (87.77%) or one severe and one mild/variable mutation (11.33%), whereas CBAVD men had either a severe and a mild/variable (87.89%) or two mild/variable (11.57%) mutations. Copyright 2000 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10923036     DOI: 10.1002/1098-1004(200008)16:2<143::AID-HUMU7>3.0.CO;2-J

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  36 in total

1.  An ancient founder mutation in PROKR2 impairs human reproduction.

Authors:  Magdalena Avbelj Stefanija; Marc Jeanpierre; Gerasimos P Sykiotis; Jacques Young; Richard Quinton; Ana Paula Abreu; Lacey Plummer; Margaret G Au; Ravikumar Balasubramanian; Andrew A Dwyer; Jose C Florez; Timothy Cheetham; Simon H Pearce; Radhika Purushothaman; Albert Schinzel; Michel Pugeat; Elka E Jacobson-Dickman; Svetlana Ten; Ana Claudia Latronico; James F Gusella; Catherine Dode; William F Crowley; Nelly Pitteloud
Journal:  Hum Mol Genet       Date:  2012-07-05       Impact factor: 6.150

2.  Best practice guidelines for molecular genetic diagnosis of cystic fibrosis and CFTR-related disorders--updated European recommendations.

Authors:  Els Dequeker; Manfred Stuhrmann; Michael A Morris; Teresa Casals; Carlo Castellani; Mireille Claustres; Harry Cuppens; Marie des Georges; Claude Ferec; Milan Macek; Pier-Franco Pignatti; Hans Scheffer; Marianne Schwartz; Michal Witt; Martin Schwarz; Emmanuelle Girodon
Journal:  Eur J Hum Genet       Date:  2008-08-06       Impact factor: 4.246

3.  Effects of gender and age at diagnosis on disease progression in long-term survivors of cystic fibrosis.

Authors:  Jerry A Nick; Cathy S Chacon; Sara J Brayshaw; Marion C Jones; Christine M Barboa; Connie G St Clair; Robert L Young; David P Nichols; Jennifer S Janssen; Gwen A Huitt; Michael D Iseman; Charles L Daley; Jennifer L Taylor-Cousar; Frank J Accurso; Milene T Saavedra; Marci K Sontag
Journal:  Am J Respir Crit Care Med       Date:  2010-05-06       Impact factor: 21.405

Review 4.  Relevance of genetic investigation in male infertility.

Authors:  P Asero; A E Calogero; R A Condorelli; L Mongioi'; E Vicari; F Lanzafame; R Crisci; S La Vignera
Journal:  J Endocrinol Invest       Date:  2014-01-24       Impact factor: 4.256

5.  Prenatal screening of Cystic Fibrosis: a single centre experience.

Authors:  Domenico Bizzoco; Alvaro Mesoraca; Antonella Cima; Monica Sarti; Gianluca Di Giacomo; Giovanna Scerra; Maria Antonietta Barone; Manuela Di Natale; Ivan Gabrielli; Caterina Tamburino; Claudia Scargiali; Cristina Ernandez; Maria Pia D'Aleo; Michele Todini; Rita Pompili; Luisa Mobili; Lucia Mangiafico; Ornella Carcioppolo; Claudio Coco; Pietro Cignini; Laura D'Emidio; Alessandra Girgenti; Cristiana Brizzi; Alessandro Cavaliere; Claudio Giorlandino
Journal:  J Prenat Med       Date:  2008-01

Review 6.  Congenital bilateral absence of the vas deferens as an atypical form of cystic fibrosis: reproductive implications and genetic counseling.

Authors:  D A S de Souza; F R Faucz; L Pereira-Ferrari; V S Sotomaior; S Raskin
Journal:  Andrology       Date:  2017-12-07       Impact factor: 3.842

7.  A neutral variant involved in a complex CFTR allele contributes to a severe cystic fibrosis phenotype.

Authors:  Jérôme Clain; Jacqueline Lehmann-Che; Emmanuelle Girodon; Joanna Lipecka; Aleksander Edelman; Michel Goossens; Pascale Fanen
Journal:  Hum Genet       Date:  2005-03-03       Impact factor: 4.132

8.  Localization studies of rare missense mutations in cystic fibrosis transmembrane conductance regulator (CFTR) facilitate interpretation of genotype-phenotype relationships.

Authors:  Kristina V Krasnov; Maria Tzetis; Jie Cheng; William B Guggino; Garry R Cutting
Journal:  Hum Mutat       Date:  2008-11       Impact factor: 4.878

9.  Molecular consequences of cystic fibrosis transmembrane regulator (CFTR) gene mutations in the exocrine pancreas.

Authors:  N Ahmed; M Corey; G Forstner; J Zielenski; L-C Tsui; L Ellis; E Tullis; P Durie
Journal:  Gut       Date:  2003-08       Impact factor: 23.059

10.  Does the genetic and familial background of males undertaking ICSI affect the outcome?

Authors:  M Maiburg; B Alizadeh; P Kastrop; M Lock; S Lans; J Giltay
Journal:  J Assist Reprod Genet       Date:  2009-06-23       Impact factor: 3.412

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.